THREE CITIES RESEARCH
Three Cities Research is a private equity firm that invests in a wide range of industries ranging from industrial manufacturing to retail.
THREE CITIES RESEARCH
Industry:
Finance Financial Services Manufacturing
Founded:
1976-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.tcr-ny.com
Total Employee:
1001+
Status:
Active
Contact:
+1 212-838-9660
Email Addresses:
[email protected]
Technology used in webpage:
SPF LetsEncrypt Nginx Microsoft Exchange Online Google Office 365 Mail Google Cloud Microsoft Azure DNS Network Solutions DNS
Similar Organizations
Ancor Capital Partners
Ancor Capital Partners is a private equity firm that specializes in the acquisition of lower middle-market companies.
Cascade Consolidated Industries
Cascade Consolidated Industries is a private investment group specializing in the investment and acquisition of manufacturing companies.
Nahla Capital
Nahla Capital is a real estate private equity firm that invests and manages capital in core urban markets.
Official Site Inspections
http://www.tcr-ny.com
- Host name: 37.14.174.34.bc.googleusercontent.com
- IP address: 34.174.14.37
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Three Cities Research"
Three Cities Research, Inc.
Three Cities Research, Inc. (TCR) is a private equity firm that has invested in private businesses since the 1970s. We have invested in a wide variety of industries, including industrial manufacturing, distribution, apparel, publishing, …See details»
Three Cities Research, Inc. - tcr-ny.com
Bill joined TCR in 1984 and has served as the managing partner since 2003. He has been involved in all aspects of the development and operation of TCR. Bill holds a BS degree in Aeronautical and Astronautical Engineering from Purdue …See details»
TCRC
Traditional Culture Reviving Center is a not-for-profit 501(c)(3) organization established to promote, restore and revive traditional culture. Our main goal is to foster public interest and …See details»
Three Cities Research - Massinvestor Venture Capital and Private …
Formed in 1976, Three Cities Research is a New York-based private equity firm with approximately $700 million of funds under management. For more than three decades TCR …See details»
TCR Holdings LLC Company Profile | New York, NY | Competitors ...
Find company research, competitor information, contact details & financial data for TCR Holdings LLC of New York, NY. Get the latest business insights from Dun & Bradstreet.See details»
Three Cities Research investment portfolio | PitchBook
Jul 17, 2024 www.tcr-ny.com. Year Founded. 1976. Investor Status. Actively Seeking New Investments. Primary Investor Type. PE/Buyout. Other Investor Types. Family Office. …See details»
TCR
RIVERDALE, NY 10463 www.tcr-nyc.com 718-796-9099 2600 NETHERLAND AVE RIVERDALE, NY 10463 ph: 718 -7969099 fax: 9530 www.tcr-nyc.com CLUB OPENS MON-FRI 6:00 AM ...See details»
Tennis - TCR-NYC
Schedule a private tour of TCR's world class facilities and discover the value membership offers! SCHEDULE PRIVATE TOUR. PHOTO GALLERY. Looking for more pictures of our facility? This is the place! ... Riverdale, NY 10463. …See details»
After School Learn & Play - TCR-NYC
Schedule a private tour of TCR's world class facilities and discover the value membership offers! SCHEDULE PRIVATE TOUR. PHOTO GALLERY. Looking for more pictures of our facility? This is the place! ... Riverdale, NY 10463. …See details»
The Climate Registry - Home Page
The Climate Registry (TCR) is a nonprofit organization that is more than just your greenhouse gas reporting platform, we are your community of climate leaders, your partners on the road …See details»
Three Cities Research, Inc. - tcr-ny.com
Finn. Finn is a manufacturer of specialty equipment and supplies for the environmental, erosion control, landscape and landfill industries. Headquarters: Fairfield, Ohio Primary TCR contact: …See details»
Tennis Leagues - Tennis Club of Rochester
Indoor leagues are open to TCR Tennis members only and offer weekly social play tennis matches. We offer a variety of membership options to keep players out on our 20 outdoor clay …See details»
O16-2 Phase I trial of NY-ESO-1 TCR-T cell therapy combined with ...
TBI-1301 is an NY-ESO-1 157–165 /HLA-A*02:01 or -A*02:06 specific TCR engineered T cell using the siRNA vector to reduce endogenous TCR expression. CHP:NE1 consists of the NY …See details»
NY-ESO-1靶点安全、有效TCR-T项目寻求合作 - 药时代
Apr 3, 2023 药时代此次推荐的NY-ESO-1项目是一款处于临床前阶段的TCR-T项目，候选药物相比1G4c259TCR具有更强的Functional Avidity并在多个肿瘤模型显示出相比1G4c259TCR更强 …See details»
Structural characterization of two γδ TCR/CD3 complexes
Jan 2, 2025 a Left and middle: two views of a 3.27 Å resolution map of the G115 TCR/CD3 complex bound by OKT3 fab. Right: cryoEM map was Gaussian filtered to 2.5 σ and the …See details»
NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With …
Jul 12, 2021 NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With Nivolumab PD-1 Blockade Status: Completed. Phase of Trial: Phase I Latest Information Update: 06 Nov 2021. …See details»
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell
Jun 15, 2023 In the phase 1 trial, autologous New York esophageal squamous cell carcinoma 1 (NY-ESO-1)-specific TCR-T cells were infused twice into HLA-matched patients with NY-ESO …See details»
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced …
Patients' tumors will be required to express NY-ESO-1, which include but is not limited to ovarian cancer, synovial sarcoma, esophageal cancer, lung cancer, bladder cancer, liver cancer, and …See details»
RCSB PDB - 9CQ8: Dimeric 9C2 gamma delta TCR extracellular …
Jul 19, 2024 Dimeric 9C2 gamma delta TCR extracellular domain bound by Fab 2 ... and 9C2 (Vγ5 Vδ1), in complex with CD3 subunits. Our results show that the overall subunit …See details»
Kite Pharma Announces Exclusive License with The National …
Kite Pharma Announces Exclusive License with The National Institutes of Health for T Cell Receptor TCR Based Products Targeting NY ESO 1 For Multiple Cancer IndicationsSee details»